Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Clinical Trial Material (CTM) Receipt Log – V 2.0

Posted on By

BA-BE Studies: SOP for Clinical Trial Material (CTM) Receipt Log – V 2.0

Standard Operating Procedure for Clinical Trial Material (CTM) Receipt Log in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/132/2025
Supersedes SOP/BA-BE/132/2022
Page No. Page 1 of 8
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a standardized procedure for receiving and logging Clinical Trial Material (CTM) used in BA/BE studies, ensuring traceability, accountability, and compliance with GCP and regulatory requirements.

2. Scope

This SOP applies to all BA/BE study-related clinical sites, pharmacy staff, clinical research coordinators, and investigators responsible for receiving investigational product (IP) and related materials at the study site.

3. Responsibilities

  • Pharmacist-in-Charge: Ensures accurate logging and verification of received CTM.
  • Site Coordinator: Assists in physical inspection and documentation during CTM receipt.
  • Principal Investigator (PI): Verifies CTM receipt records and ensures proper storage.
  • QA Officer: Audits receipt logs and reviews any discrepancies or damage reports.
See also  BA-BE Studies: SOP for Handling Inquiries from Regulatory Agencies - V 2.0

4. Accountability

The Clinical Supply Manager or designated person is accountable for ensuring proper documentation, reconciliation, and traceability of CTM from the point of receipt to final usage or disposal.

5. Procedure

5.1 Preparation for CTM Receipt

  1. Receive advance shipment notification from sponsor/CRO including:
    • Shipment date
    • Tracking number
    • Expected quantity and batch details
  2. Ensure designated receipt area is clean, temperature-monitored, and secure.

5.2 CTM Receipt and Verification

  1. Upon delivery, inspect the shipment for:
    • Correct labeling and condition of the package
    • Temperature indicator status (if cold chain)
    • Seals and tamper-evident closure integrity
  2. Open the shipment in the presence of PI or delegate.
  3. Record the details in Annexure-1: CTM Receipt Log including:
    • Date and time of receipt
    • CTM name, strength, batch number
    • Quantity received
    • Temperature at receipt
    • Remarks on condition/damages (if any)

5.3 Handling of Discrepancies or Damages

  1. Note discrepancies/damages in Annexure-2: CTM Discrepancy Report Form.
  2. Photograph the damaged material (if applicable).
  3. Quarantine the affected CTM and label accordingly.
  4. Inform sponsor or CRO within 24 hours and await further instructions.
See also  BA-BE Studies: SOP for IMP Destruction or Return Process - V 2.0

5.4 Storage and Labeling

  1. Store received CTM as per sponsor-specified conditions (e.g., 2–8°C, ambient, -20°C).
  2. Label shelves/storage cabinets with CTM name, batch number, and expiry date.
  3. Update storage log and ensure access control to CTM storage area.

5.5 Reconciliation and Audit Readiness

  1. Maintain updated running inventory in Annexure-3: CTM Inventory Log.
  2. Ensure batch-wise reconciliation after dosing completion and at study close-out.
  3. Ensure CTM Receipt Log is audit-ready and securely archived in the Trial Master File (TMF).

6. Abbreviations

  • CTM: Clinical Trial Material
  • IP: Investigational Product
  • QA: Quality Assurance
  • PI: Principal Investigator
  • TMF: Trial Master File

7. Documents

  1. CTM Receipt Log – Annexure-1
  2. CTM Discrepancy Report Form – Annexure-2
  3. CTM Inventory Log – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y, Drugs and Cosmetics Act, India
  • WHO Guidelines on Good Storage and Distribution Practices
See also  BA-BE Studies: SOP for Clinical Trial Photography and Video Recording - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: CTM Receipt Log

Date CTM Name Batch No. Qty Received Storage Condition Received By
16/04/2025 Metformin 500 mg B23M001 200 blisters Ambient Sunita Reddy

Annexure-2: CTM Discrepancy Report Form

Date CTM Name Issue Identified Action Taken Notified To
16/04/2025 Placebo Blister Damaged seal Quarantined CTM Manager

Annexure-3: CTM Inventory Log

Date CTM Name Batch No. Received Used Balance Checked By
17/04/2025 Metformin 500 mg B23M001 200 50 150 Ajay Verma

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial SOP Release Compliance with CTM handling QA Head
17/04/2025 2.0 Added discrepancy handling and storage documentation requirements Regulatory Alignment QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Analytical Method Development: Complexometric Titration Method Development – V 2.0
Next Post: Biosimilars: SOP for Media Preparation and Sterilization – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version